Subject: R | Biochemistry, Genetics and Molecular Biology(all) | Medicine(all) | Medicine | Technical Note | Biology (General) | QH301-705.5
mesheuropmc: integumentary system
<p>Abstract</p> <p>Background</p> <p>Recombinant tissue plasminogen activator (tPA) is a thrombolytic widely used clinically in the treatment of acute thrombotic disease such as ischemic stroke, myocardial infarction, and deep venous thrombosis. This has led to much int... View more
Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, et al.: Guidelines for Thrombolytic Therapy for Acute Stroke: a Supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke 1996, 27(9):1711-1718.
Pancioli AM, Brott TG: Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke: scientific rationale and available evidence. CNS drugs 2004, 18(14):981-988.
Loren M, Fade-Garcia LJ, Toorado MC, Navarro JL: Thrombus age and tissue plasminogen activator mediated thrombolysis in rats. Thrombosis Research 1989, 56:67-76.
Jaffe GJ, Green GD, Abrams GH: Stability of recombinant tissue plasminogen activator. American Journal of Ophthalmology 1989, 108(1):90-91.
Wiernikowski JT, Crowther M, Clase CM, Ingram A, Andrew M, Chan AK: Stability and sterility of recombinant tissue plasminogen activator at -30 degrees C. Lancet 2000, 355(9222):2221-2222.